Keywords
How to Cite
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous reproductive– metabolic disorder in which insulin resistance, hyperinsulinemia, androgen excess, altered adipose biology and ovarian dysfunction interact rather than operate as independent abnormalities. Objective: To critically synthesize the mechanistic bidirectionality of insulin resistance and hyperandrogenism and examine how randomized trials, real-world evidence and computational methods may refine disease stratification and treatment evaluation. Methods: A structured, non -systematic evidence synthesis prioritized the 2023 International Evidence-based PCOS Guideline, indexed mechanistic reviews, randomized-trial syntheses and regulatory documents concerning real-world evidence and artificial intelligence.
References
1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International
Evidence-based Guideline for the Assessment and Management of Polycystic Ovary
Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463.
2. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International vidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1655-1679. doi:10.1093/humrep/dead156. [Parallel publication of reference 1; not independent evidence.]
This work is licensed under a Creative Commons Attribution 4.0 International License.
